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Purpose
The recent discovery and characterization of an oncogenic ROS1 gene rearrangement has
raised significant interest because small molecule inhibitors are effective in these tumors.
The aim of this study was to determine frequency and clinicopathological features associ-
ated with ROS1 rearrangement in patients with cholangiocarcinoma (CCA). 
Materials and Methods
A total of 261 patients who underwent surgery for CCA between October 1997 and August
2013 were identified from an international, multi-institutional database. ROS1 rearrange-
ment was evaluated by break-apart fluorescence in situ hybridization using tissue microar-
rays of these patients. 
Results
Of 261 CCA evaluated, three cases (1.1%) showed ROS1 rearrangement by fluorescence
in situ hybridization (FISH), all of which were derived from intrahepatic origin. ROS1 protein
expression was observed in 38 samples (19.1%). Significantly larger tumor size was 
observed in ROS1 immunohistochemistry (IHC)–negative patients compared with ROS1
IHC–positive patients. ROS1 FISH–positive patients had a single tumor with a median size
of 4 cm and well-to-moderate differentiation. Overall, there was no difference in terms of
baseline characteristics, overall survival, and recurrence-free survival between ROS1-posi-
tive and -negative patients.
Conclusion
ROS1 rearrangement was detected in 1.1% of CCA patients. Although rare, conduct of clin-
ical trials using ROS1 inhibitors in these genetically unique patients is warranted. 
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Introduction
Cholangiocarcinoma (CCA) is a lethal biliary tract cancer
[1]. The age-adjusted incidence rate is 3.3 per 100,000 among
Asians, and despite the relatively low incidence, the overall
incidence of CCA is increasing worldwide [2,3]. CCA is gen-
erally regarded as a surgical disease, and surgical resection
offers the only chance for long-term survival [4]. However,
most patients are diagnosed with advanced-stage disease,
which limits the treatment options. In addition, even after
curative-intent surgery, the survival outcomes are disap-
pointing with a 5-year survival rate of 20%-30% [5]. Combi-
nation chemotherapy with gemcitabine and a platinum agent
is regarded as a standard first-line treatment [6]; however,
the prognosis is still poor and overall survival (OS) remains
less than 12 months. Therefore, efforts to improve outcomes
for CCA by incorporating novel targeted therapeutics are 
urgently needed. 
Contemporary research techniques have enabled identifi-
cation of several markers involved in molecular pathogenesis
of CCA [7]. In a recent study from Singapore, 206 somatic
mutations were identified through exome sequencing of
liver-fluke associated CCA [8]. TP53 accounted for the most
common cancer-related gene (44%), followed by KRAS (17%)
and SMAD4 (17%). Genetic alterations associated with deac-
tivation of histone modifiers including ARID1A (9%) were
also identified. However, none of these genetic alterations is
amenable to targeted therapy. Recently, in the first phase 3
trial to assess a targeted therapy plus chemotherapy combi-
nation, improvement in OS was not observed by treatment
with gemcitabine and oxaliplatin with or without erlotinib.
Only a small improvement in median progression-free sur-
vival was observed in a subset of patients with CCA (5.9
months vs. 3.0 months) [9], and there was no distinct predic-
tive biomarker for erlotinib response in this study.
ROS1 rearrangements were recently detected in CCA 
patient tissues, suggesting that this could play a role as a
driver oncogene. The reported incidence of ROS1 rearrange-
ment was 8.7% of CCA patients [10]. Interestingly, fused-
in-glioblastoma-c-ros-oncogene 1 (FIG-ROS) fusion acceler-
ated cholangiocarcinogenesis in mouse models [11], support-
ing ROS1 as a novel therapeutic target in CCA. ROS1
rearrangement was previously detected in other solid tumors
including non-small-cell lung cancer (NSCLC) and glioblas-
toma [12-14]. To date, nine different ROS1 fusion partners
have been identified, all of which are potentially targetable
due to the intact cytoplasmic portion of the ROS1 tyrosine
kinase domain [15]. Due to the biological similarity of ROS1
and anaplastic lymphoma kinase (ALK), inhibition of ROS1
by several ALK inhibitors has been demonstrated [16]. 
Recent data from a phase 1 trial of crizotinib in the ROS1-
positive NSCLC expansion cohort showed an overall 
response rate of 72% [17]. Therefore, identification of ROS1
rearrangement in CCA could offer a new therapeutic option
in treatment of this fatal disease. 
The current study uses the largest data set yet generated
of CCA. The aim of this study was to determine the fre-
quency of ROS1 rearrangement and to evaluate clinicopatho-
logical features associated with ROS1 rearrangement in CCA
patients. 
Materials and Methods
1. Patients  
A total of 261 patients with CCA who underwent surgical
resection with curative intent between October 1997 and 
August 2013 were identified at two institutions (Yonsei Uni-
versity College of Medicine, Seoul, Korea; National Univer-
sity of Singapore, Singapore). The database was reviewed
retrospectively and only patients with histologically con-
firmed CCA and available tissue for ROS1 analysis were 
included. Patient records/information was anonymized and
de-identified prior to analysis. This study was approved by
the Institutional Review Boards of Severance Hospital and
Singapore General Hospital and the requirement for consent
was waived. 
Out of 261 patients, 242 patients (93%) were available for
ROS1 analysis. Standard demographic and clinicopathologic
data were collected, including sex, age, and primary tumor
characteristics. Specifically, data were collected on primary
tumor location, size, and number as well as morphologic
subtype and presence of vascular invasion, biliary invasion,
lymph node involvement, and stage. Staging was done 
according to the seventh edition of the American Joint Com-
mittee on Cancer/Union for International Cancer Control
staging manual. Dates related to treatment including sur-
gery, recurrence, and last follow-up were collected on all 
patients. OS was measured from the date of diagnosis until
the date of death and recurrence-free survival (RFS) was meas-
ured from the date of surgery until the date of recurrence. 
2. Tissue microarrays
The tumor samples were fixed in 10% buffered formalin,
processed, and embedded in paraffin using the standard pro-
tocol [18]. All hematoxylin and eosin–stained slides were 
reviewed, and representative areas were carefully selected
and marked on individual paraffin blocks. Three 3.0-mm tis-
sues cores were taken from each tumor specimen.
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3. ROS1 fluorescence in situ hybridization
For identification of ROS1 rearrangement, fluorescence in
situ hybridization (FISH) assays were performed using a
break-apart probe to ROS1 (Break-Apart Rearrangement
Probe, Abbott Molecular, Des Plaines, IL) according to the
manufacturer’s instructions using tissue microarrays. At
least 100 nuclei of tumor cells per case were evaluated. FISH
positivity for ROS1 rearrangement was defined as > 15% of
tumor cells with a split signal or > 15% of single green sig-
nals. FISH studies were interpreted by two experienced eval-
uators (J.E.Y. and Y.N.P.) who were blinded to the clinical
data. 
4. Immunohistochemical staining
Protein expression of ROS1 was detected by immunohis-
tochemical staining in the Korean cohort, and it was not per-
formed in the Singapore cohort due to lack of unstained
slides. Tissue microarray sections were stained using the
Ventana automated immunostainer BenchMark XT (Ventana
Medical Systems, Tucson, AZ). The slides were dried at 60°C
for 1 hour and deparaffinized using EZ Prep (Ventana Med-
ical Systems) at 75°C for 4 minutes. Cell conditioning was
performed using CC1 solution (Ventana Medical Systems) at
100°C for 8 minutes. ROS1 antibody (rabbit monoclonal,
clone D4D6, Cell Signaling Technology, Danvers, MA) was
diluted to 1:10, followed by treatment, and incubation at
37°C for 2 hours. Signals were detected using the OptiView
DAB IHC Detection Kit (Ventana Medical Systems). Coun-
terstaining was performed using Hematoxylin I (Ventana
Medical Systems) for 4 minutes at room temperature. 
5. Statistical analysis
Statistics were obtained using established methods and
presented as percentages, mean, or median values. Survival
was estimated using the Kaplan-Meier method for the 
median and 95% confidence interval (CI); comparison 
between groups was performed using a two-sided log-rank
test. Fisher exact test, t test, or Mann-Whitney U test were
used for comparison of differences between groups. p-values
of  0.05 were considered statistically significant. Statistical
analyses were performed using SPSS ver. 20.0 (IBM Co., 
Armonk, NY).
Results
1. Patient characteristics
The clinicopathological features of 261 patients including
208 intrahepatic CCAs and 53 extrahepatic CCAs are shown
in Table 1. The median age of all patients was 65.6 years and
males (56%) were predominant compared with females
(44%). The majority of patients presented with intrahepatic
CCAs (80%), a single tumor (81%) with a median tumor size
of 4.6 cm. The tumor was well-to-moderately differentiated
in 80% of patients. Lymphadenectomy was performed in 209
patients (80%), and 67 patients (32%) presented with lymph
node positive disease. The median preoperative carbohy-
drate antigen 19-9 level was 71.9 U/mL (range, 0 to 20,000
U/mL; reference value,  37 U/mL). In comparison of sam-
ples from the Korea and Singapore cohorts (Supplementary
Table 1), no significant difference in clinicopathological fea-
tures was observed between the two cohorts. 
2. Break-apart FISH and immunohistochemical analysis of
ROS1
Among 261 patients screened for ROS1 rearrangement, 245
cases were analyzed by FISH (detection rate, 93.9%), and
Table 1. Demographic and clinical characteristics of 
patients 
Variable No. (%) (n=261)
Age, median (range, yr) 65.6 (33-91)
Sex
Male 148 (56)
Female 113 (44)
Tumor location
Intrahepatic 208 (80)
Extrahepatic 53 (20)
Tumor size, median (range, cm) 4.6 (0.8-15)
Multiple tumors 51 (19)
Tumor differentiation
Well-moderately differentiated 211 (80)
Poorly differentiated 50 (20)
Lymph node disease 67/209 (32)
CA19-9, median (range, U/mL) 71.9 (0-20,000)
Stage
I 88 (34)
II 55 (21)
III 23 (9)
IV 95 (36)
CA19-9, carbohydrate antigen 19-9.
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FISH signal was not detected in 16 cases due to sample qual-
ity. Three cases showed ROS1-positivity (1.2%) by FISH; 
patients 1 and 2 showed break-apart signals, while patient 3
showed a single signal as shown in Fig. 1. Comparison of
ROS1-negative and -positive patients showed no significant
differences in baseline demographic and clinical characteris-
tics. For immunohistochemistry (IHC) analysis, 198 cases
were available for analysis of ROS1 protein expression. ROS1
protein expression was observed in 38 samples (19.1%).
Comparison of ROS1-negative and -positive patients showed
a significant difference in tumor size, while there was no dif-
ference in other parameters. ROS1-negative patients had a
significantly larger tumor size than ROS1-positive patients
(p=0.025) (Supplementary Table 2). Of note, among three
ROS1 FISH–positive cases, two patients (66.7%) showed
ROS1 immunoreactivity (Fig. 1). The sensitivity for the 
detection of ROS1 rearranged CCA was 66.7% with 81.5%
specificity.
3. Clinical outcome of patients
The clinical outcomes of all patients and ROS1-positive
versus ROS1-negative patients were compared. The median
OS was 36.6 months (95% CI, 26.8 to 46.3 months), and the
median RFS was 9.9 months (95% CI, 7.5 to 12.4 months) for
all patients (Fig. 2A and B). There were no statistical differ-
ences in terms of OS and RFS (Fig. 2C and D) between ROS1
FISH–positive and ROS1 FISH–negative patients, and there
was no statistical difference in terms of OS and RFS between
ROS1 IHC–positive and ROS1 IHC–negative patients.
4. Analysis of ROS1 FISH–positive patients
A detailed summary of the clinicopathological data of
three patients with ROS1 rearrangement is shown in Table 2.
These patients were all intrahepatic CCA, and no signs of 
hepatolithiasis and parasitic infection were detected. 
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Fig. 1. Representative ROS1 rearrangement features in cholangiocarcimomas. Fluorescence in situ hybridization (FISH)
showing ROS1 rearrangement with break-apart signals in patients 1 and 2 and single green signals in patient 3. FISH showing
ROS1 rearrangement with break-apart signals in low-power field  (A, F, K) and high-power field (B, G, L). FISH showing
ROS1 rearrangement with single green signals (K, L). The arrows indicate ROS1 break-apart or single green signals (A, F,
K, 400; B, G, L, 630). Immunohistochemical stain for ROS1 in ROS1 rearranged cholangiocarcinoma (C, H, M, 200). 
Microscopic features (D, I, N, H&E staining, 200) and photographs of surgical specimens (E, J, O) are also shown. 
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Patient 1 had a 6.5-cm-sized mass forming tumor with
moderate differentiation. Patient 2 had a 3-cm-sized CCA
with intraductal growth and well differentiation. Patient 3
had a 3-cm-sized CCA with periductal infiltrative growth
and moderate differentiation. Patients 1 and 3 showed lymph
node metastasis of CCA. 
Discussion
In this study, we screened CCA tissue archives and found
that approximately 1.1% of CCA patients harbored ROS1
rearrangement. Of note, all ROS1-positive patients had 
intrahepatic CCA. To date, this is the first large-scale screen-
ing effort to examine the frequency of ROS1 rearrangement
in CCA patient tissue.
CCA is a fatal disease with a huge unmet need for novel
therapeutics and efforts have been made to define genetic
sub-classification of CCA. The potentially targetable signal-
ing pathways in CCA include EGFR, VEGF, HER2/neu, MET,
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Fig. 2. Survival analysis. (A) Kaplan-Meier curve of median overall survival (OS) of all patients. (B) Kaplan-Meier curve of
median recurrence-free survival (RFS) of all patients. (C) Comparison of OS between ROS1-positive and -negative patients.
(D) Comparison of RFS between ROS1-positive and -negative patients. CI, confidence interval.
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AKT, PI3K/mTOR, MEK, PARP1/2, IDH1, and IDH2 [1]. How-
ever, clinical trials targeting these genetic alterations have
not been successful in proving survival benefit. Combina-
tions of doublet chemotherapy with anti-EGFR agents have
shown modest results, and responses with small molecule
inhibitors are limited. Use of erlotinib, lapatinib, sorafenib,
cetuximab, and bevacizumab has been attempted in biliary
tract cancer patients, but the response rates are between 
0%-12%, median progression-free survival of 1.8 to 3.7
months, and median OS of 4.4 to 9.8 months. Therefore,
greater effort is required for identification of genomically 
homogenous patient subsets who would benefit from spe-
cific targeted agents. 
The discovery and characterization of ROS1 rearrange-
ment in CCA has attracted significant clinical interest 
because small molecule inhibitors have effective antitumor
activity. Because ALK and ROS1 share an approximately 49%
amino acid sequence in the kinase domain, ALK inhibitors
have been proved to be effective in inhibiting ROS1 activity
[16]. In addition, an orthotopic allograft mouse model of 
intrahepatic CCA validated FIG-ROS1 fusion as a potent
oncogene where it cooperates with KRAS and mutant p53 to
accelerate tumor onset [11]. These results suggest that ROS1
rearrangement in CCA may be a promising druggable target
requiring further investigation.  
While nine fusion partners to ROS1 have been identified
(FIG, CCDC6, CD74, EZR, KDELR2, LRIG3, SLC34A2, SDC4,
and TPM3), all of which retain the ROS1 cytoplasmic kinase
domain [15,16], only FIG-ROS1 fusion transcript has been
identified in CCA so far. The frequency of ROS1 rearrange-
ment in CCA has not yet been well-defined. Gu et al. [10],
who screened for ROS1 rearrangement by reverse transcrip-
tase-polymerase chain reaction (RT-PCR) in CCA patients,
reported the frequency of FIG-ROS1 rearrangement as 8.7%
(2 out of 23). However, Arai et al. [18] recently reported that
the FIG-ROS1 fusion in CCA was 0% when screened by 
RT-PCR in 102 patients. We report the frequency of ROS1
rearranged tumors as 1.1% in the largest cohort ever. Despite
its low incidence, we agree that ROS1 rearrangements war-
rant a new molecular subtype of CCA. Indeed, the results of
an ongoing clinical trial of a drug targeting ROS1 rearrange-
ment in CCA patients are eagerly awaited (NCT02374489). 
Regarding the screening method of ROS1 rearrangement,
FISH and RT-PCR have been commonly used, although time
consuming, costly, and not suitable for massive screening.
Accurate identification of ROS1-rearranged cancers by IHC
analyses using an anti-ROS1 rabbit monoclonal antibody
(D4D6) showing 100% (8/8) sensitivity and 100% (138/138)
specificity when compared with break-apart FISH in lung
cancer was recently reported [19]. However, there are no con-
crete data validating the screening utility of IHC in CCA. 
In a recent study IHC screening of ROS1 expression in intra-
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hepatic CCA showed 37.1% (72/194) positivity, but all were
FISH-negative [20]. Similarly, in our study incidence of ROS1
protein expression was significantly higher than gene 
rearrangement (19.1% vs. 1.2%). As protein expression of
ROS1 may result from amplification and epigenetic changes,
we should be cautious in interpreting results of ROS1 
immunohistochemistry in CCA. For now, IHC cannot be an
efficient screening method, and further validation with 
respect to ROS1 diagnostics should be established in the 
future. 
The limitation of this study is the lack of information on
the fusion variants in ROS1-positive samples, which was due
to insufficient tissue samples and poor quality of extracted
RNA in formalin-fixed, paraffin-embedded tumors.
Conclusion
In conclusion, we screened for ROS1 rearrangement in the
largest-ever international of cohort of 261 CCAs including
208 intrahepatic CCAs and 53 extrahepatic CCAs. ROS1
rearrangement was detected in 1.2% of total CCAs and 1.4%
of intrahepatic CCAs. Our results indicate that future screen-
ing efforts may offer a new therapeutic option for advanced
CCA patients. Further investigation on the impact of ROS1
inhibition on the survival of CCA patients harboring ROS1
rearrangements is necessary. 
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